{
  "pmcid": "6781206",
  "sha256": "7475b57881a6587496f401b0e14250de4a78f6aeda34958258b94f5b8b591b50",
  "timestamp_utc": "2025-11-09T16:10:38.963977+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 7.458224215246641,
    "reading_ease": 68.0699970104634,
    "word_count": 223
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients with occipital headache were divided into two groups (bupivacaine: BUP group [n = 27], botulinum toxin: BTX group [n = 27])"
      },
      "Participants": {
        "score": 1,
        "evidence": "Patients with occipital headache"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients with occipital headache were divided into two groups (bupivacaine: BUP group [n = 27], botulinum toxin: BTX group [n = 27])"
      },
      "Objective": {
        "score": 1,
        "evidence": "Our study presents the long-term effect of botulinum toxin on GON block using ultrasound in patients with chronic headache in occipital area."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Visual analogue scale (VAS) scores and Likert scale were assessed at pretreatment and at 1, 4, 8, and 24 weeks after treatment in both groups."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Patients with occipital headache were divided into two groups (bupivacaine: BUP group [n = 27], botulinum toxin: BTX group [n = 27])"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The VAS score and patient satisfaction score (Likert scale) in 4, 8, and 24 weeks after injection were superior for the BTX than the BUP group."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 10,
    "max_score": 25
  }
}